世界における先天的遺伝子変異または先天的染色体変異検査製品のパイプライン動向2015...市場調査レポートについてご紹介

【英文タイトル】Inborn Gene or Chromosome Alterations - Pipeline Review, 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Inborn Gene or Chromosome Alterations Overview 11
3 Products under Development 12
3.1 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 12
3.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 13
3.3 Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 14
3.4 Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 15
3.5 Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 16
4 Inborn Gene or Chromosome Alterations – Pipeline Products under Development by Companies 17
4.1 Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 17
4.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 20
5 Inborn Gene or Chromosome Alterations Companies and Product Overview 23
5.1 AC-Gen Reading Life S.L. Company Overview 23
5.1.1 AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Admera Health, LLC Company Overview 24
5.2.1 Admera Health, LLC Pipeline Products & Ongoing Clinical Trials Overview 24
5.3 Agena Bioscience, Inc Company Overview 25
5.3.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.4 Ariosa Diagnostics, Inc. Company Overview 29
5.4.1 Ariosa Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
5.5 Atomic International Company Overview 30
5.5.1 Atomic International Pipeline Products & Ongoing Clinical Trials Overview 30
5.6 Baylor College of Medicine Company Overview 31
5.6.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 31
5.7 BCML GmbH Company Overview 33
5.7.1 BCML GmbH Pipeline Products & Ongoing Clinical Trials Overview 33
5.8 BioCeps (Inactive) Company Overview 34
5.8.1 BioCeps (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 CardioDx, Inc. Company Overview 35
5.9.1 CardioDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Celera Corporation Company Overview 37
5.10.1 Celera Corporation Pipeline Products & Ongoing Clinical Trials Overview 37
5.11 Celula, Inc. Company Overview 41
5.11.1 Celula, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.12 Children’s Hospital Boston Company Overview 42
5.12.1 Children’s Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.13 China Medical Technologies, Inc. Company Overview 45
5.13.1 China Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
5.14 Da An Gene Co., Ltd. Company Overview 48
5.14.1 Da An Gene Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48
5.15 Dana-Farber Cancer Institute, Inc. Company Overview 51
5.15.1 Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.16 Epinex Diagnostics Incorporated Company Overview 53
5.16.1 Epinex Diagnostics Incorporated Pipeline Products & Ongoing Clinical Trials Overview 53
5.17 Genentech, Inc. Company Overview 54
5.17.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.18 German Cancer Research Center Company Overview 55
5.18.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 55
5.19 GILUPI Nanomedizin Company Overview 57
5.19.1 GILUPI Nanomedizin Pipeline Products & Ongoing Clinical Trials Overview 57
5.20 Hadassah Medical Center Company Overview 58
5.20.1 Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview 58
5.21 Helicos BioSciences Corporation Company Overview 59
5.21.1 Helicos BioSciences Corporation Pipeline Products & Ongoing Clinical Trials Overview 59
5.22 Illumina, Inc. Company Overview 60
5.22.1 Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.23 IntegraGen SA Company Overview 62
5.23.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 62
5.24 Interleukin Genetics, Inc. Company Overview 64
5.24.1 Interleukin Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 64
5.25 JS Genetics Inc. Company Overview 66
5.25.1 JS Genetics Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 Laboratory Corporation of America Holdings Company Overview 67
5.26.1 Laboratory Corporation of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 67
5.27 Laval University Company Overview 69
5.27.1 Laval University Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 LifeCodexx AG Company Overview 70
5.28.1 LifeCodexx AG Pipeline Products & Ongoing Clinical Trials Overview 70
5.29 Maastricht University Medical Center Company Overview 71
5.29.1 Maastricht University Medical Center Pipeline Products & Ongoing Clinical Trials Overview 71
5.30 Massachusetts Eye and Ear Infirmary Company Overview 72
5.30.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 72
5.31 Medical Research Council Company Overview 74
5.31.1 Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 74
5.32 Micromedic Technologies Ltd Company Overview 75
5.32.1 Micromedic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 75
5.33 Multiplicom N.V. Company Overview 76
5.33.1 Multiplicom N.V. Pipeline Products & Ongoing Clinical Trials Overview 76
5.34 Myriad Genetics, Inc. Company Overview 78
5.34.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
5.35 Natera, Inc. Company Overview 80
5.35.1 Natera, Inc. Pipeline Products & Ongoing Clinical Trials Overview 80
5.36 National University of Singapore Company Overview 85
5.36.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 85
5.37 NewGene Ltd Company Overview 89
5.37.1 NewGene Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
5.38 NX PharmaGen Inc. Company Overview 94
5.38.1 NX PharmaGen Inc. Pipeline Products & Ongoing Clinical Trials Overview 94
5.39 Paragon Medical, Inc. Company Overview 95
5.39.1 Paragon Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.40 Population Diagnostics Inc. Company Overview 96
5.40.1 Population Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.41 Qiagen N.V. Company Overview 100
5.41.1 Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview 100
5.42 Quantamerix Company Overview 102
5.42.1 Quantamerix Pipeline Products & Ongoing Clinical Trials Overview 102
5.43 Sapien Biosciences Company Overview 103
5.43.1 Sapien Biosciences Pipeline Products & Ongoing Clinical Trials Overview 103
5.44 Seegene, Inc. Company Overview 104
5.44.1 Seegene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 104
5.45 Sequenom, Inc. Company Overview 106
5.45.1 Sequenom, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106
5.46 Stanford University Company Overview 112
5.46.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 112
5.47 The Johns Hopkins University Company Overview 114
5.47.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 114
5.48 The Sheba Medical Center Company Overview 115
5.48.1 The Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 115
5.49 The University of Utah Company Overview 116
5.49.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 116
5.50 TrovaGene, Inc. Company Overview 117
5.50.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 117
5.51 University of Colorado Company Overview 121
5.51.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 121
5.52 University of Washington Company Overview 122
5.52.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 122
5.53 VitaPath Genetics, Inc. Company Overview 123
5.53.1 VitaPath Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 123
5.54 Xiamen Zeesan Biotech Co.,Ltd Company Overview 124
5.54.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 124
5.55 Yale University Company Overview 125
5.55.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 125
6 Inborn Gene or Chromosome Alterations- Recent Developments 126
7 Appendix 165
7.1 Methodology 165
7.2 About GlobalData 167
7.3 Contact Us 168
7.4 Disclaimer 168


【レポート販売概要】

■ タイトル:世界における先天的遺伝子変異または先天的染色体変異検査製品のパイプライン動向2015
■ 英文:Inborn Gene or Chromosome Alterations - Pipeline Review, 2015
■ 発行日:2015年10月1日
■ 調査会社:GlobalData
■ 商品コード:GDME0076EPD
■ 調査対象地域:グローバル
  • 金融部門におけるAIM(アプリケーション・インフラストラクチャ及びミドルウェア)の世界市場
    About Application Infrastructure and Middleware Middleware, also known as application infrastructure, can be defined as a set of services designed to manage complex multiple processes in organizations by enabling them to interact with each other. It plays an important role in helping IT align itself with business needs and applications. It helps organizations reinvent themselves, develop a more co …
  • 産業用冷却装置の世界市場予測(~2021)
    The global industrial cooling system market is projected to reach USD 17.24 Billion by 2021, at a CAGR of 5.0% between 2016 and 2021. This growth is mainly attributed to impressive development of power generation manufacturing industry in Asia-Pacific, increasing nuclear power generation capacities, and rising demand of cooling systems in thermal power generation industry. Power generation segment …
  • 世界のクラウド型請求(課金)ソリューション市場
    Cloud billing refers to billing solutions for digital as well as non-digital services. The flexibility of using cloud services such as Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS) anytime and anywhere has created business opportunities across various verticals but at the same time proper monetization of these services is critical so as to avoid …
  • 生物活性原料の世界市場分析:製品別(繊維、ビタミン、オメガ3 PUFA、植物エキス、ミネラル、カロテノイド・酸化防止剤、プロバイオティクス)、用途別(機能性食品・飲料、栄養補助食品、臨床栄養、パーソナルケア)、セグメント予測
    The global bioactive ingredient market is expected to reach USD 51.71 billion by 2024, according to a new report by Grand View Research, Inc. Increasing disposable income coupled with growing health awareness among consumers is expected to aid the market growth. Their functional properties are capable of acting on the human metabolism physiology by providing potential health benefits. The extracti …
  • イソシアネート(Isocyanate)の世界市場:ジフェニルメタンジイソシアネート(MDI)、トルエンジイソシアネート(TDI)、脂肪族イソシアネート
    About Isocyanates Isocyanates are highly reactive chemicals that are used to manufacture polyurethanes, which are used in various industrial and commercial sectors. The most common type of isocyanates used are Methylene Diphenyl Diisocyanate (MDI) and Toluene Diisocyanate (TDI).However, isocyanates are hazardous in nature and may cause irritation to skin, breathing problems, and may also cause whe …
  • ディーゼルポータブル発電機の世界市場2015-2019
    About generators Generators provide temporary AC or DC power by using supplied fuel such as gasoline, diesel, and gas. They can be used as a source of backup or emergency power for residential, commercial, and industrial applications. A typical generator is powered via a fuel engine. Portable generators are the best solutions to provide AC power for standby non-hardwired applications. Low-end mode …
  • Ecopetrol S.A.:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Ecopetrol S.A. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Ecopetrol S.A. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key opera …
  • コードレス造園機器の世界市場2019-2023
    About this market The continuously increasing product awareness through numerous marketing campaigns will foster the cordless garden equipment market growth during the forecast period. Campaigns against noise-generating garden equipment and growing calls for quieter alternatives will augment the market growth. Several programs are also encouraging the use of clean battery-powered lawns and garden …
  • バイオガス・アップグレード装置の世界市場2016-2020
    About the Biogas Upgrading Equipment Market Biogas is produced through anaerobic digestion of organic matter in which bacteria degrade biological material in the absence of oxygen. It is a renewable fuel that contains a mixture of methane, hydrogen sulfide, and carbon dioxide. Biogas is mostly used in farms where the waste and residue are converted into sustainable green energy. Technavio’s analys …
  • 防衛IT支出の世界市場2016-2020
    About Defense IT Spending Growing international terrorism and rising number of extremist groups are threatening many countries. Therefore, many countries are implementing advanced ICT solutions to strengthen their defense capabilities. The defense sector is also facing many challenges related to cyber security to counter online cyber-attacks from hackers. To manage a large amount of data and to pr …
  • 医療レポート:Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US-疫学予測(~2022)
    EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022 Summary Respiratory syncytial virus (RSV) is one of the most common causes of respiratory infections in children. The majority of cases present with mild, cold-like symptoms, but about 1% of cases develop severe complications requiring hospitalization. Children und …
  • 社会不安障害(SAD)治療のグローバル臨床試験動向(2014年下半期)
    Social Anxiety Disorders (SAD) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Social Anxiety Disorders (SAD) Global Clinical Trials Review, H2, 2014" provides data on the Social Anxiety Disorders (SAD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Social Anxiety Disorders (SAD). It includes an o …
  • 世界のパーソナルケア成分市場2015
    The Global Personal Care Ingredients Industry Report 2015 is a professional and in-depth study on the current state of the Personal Care Ingredients industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Personal Care Ingredients market analysis is provided for the international markets including developm …
  • 二次性進行型多発性硬化症(SPMS)の治療薬パイプライン動向(2015年上半期版)
    Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple S …
  • ネットワークアクセス制御(NAC)の世界市場2016-2020
    Technavio’s market research analyst predicts the global network access control (NAC) market to grow profoundly at a CAGR of nearly 32% by 2020. The recent rise in malware attacks on enterprise networks has forced companies to invest in NAC solutions to ensure authorized access to data. Moreover, a number of operating systems, such as iOS, Android, and Windows, have also improved their compatibilit …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。